BioInfra Co., Ltd. (KOSDAQ:199730)
South Korea · Delayed Price · Currency is KRW 3,960.00
-10.00 (-0.25%)
At close: Apr 2, 2026
BioInfra Revenue
In the year 2025, BioInfra had annual revenue of 23.15B KRW, down -2.87%. BioInfra had revenue of 6.56B in the quarter ending December 31, 2025, with 22.95% growth.
Revenue
23.15B
Revenue Growth
-2.87%
P/S Ratio
0.83
Revenue / Employee
n/a
Employees
n/a
Market Cap
19.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 23.15B | -685.20M | -2.87% |
| Dec 31, 2024 | 23.83B | -6.30B | -20.90% |
| Dec 31, 2023 | 30.13B | -5.30B | -14.96% |
| Dec 31, 2022 | 35.43B | 4.87B | 15.94% |
| Dec 31, 2021 | 30.56B | 10.95B | 55.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 74.05B |
| DreamCIS | 66.63B |
| C&R Research | 64.98B |
| DT&CRO CO. | 47.75B |
| WOOJUNG BIO | 37.59B |
| P&K Skin Research Center | 22.78B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |